Prodrugs of glutamine analogs
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F21%3A00541954" target="_blank" >RIV/61388963:_____/21:00541954 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20210323&DB=&locale=en_EP&CC=US&NR=10954257B2&KC=B2&ND=5" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20210323&DB=&locale=en_EP&CC=US&NR=10954257B2&KC=B2&ND=5</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Prodrugs of glutamine analogs
Original language description
The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US10954257
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Mar 23, 2021
Owner name
The Johns Hopkins University. - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence